The China Biotech Playbook
Six Company Archetypes, Four Intelligence Layers, and Why Human Risk Is the Deal

Locust Walk examined the evolving landscape of cross-border transactions involving Chinese biotech and what it truly takes to succeed as a global dealmaker in today’s market. As Chinese assets account for a record share of global licensing activity, understanding the intelligence gaps, company dynamics, and human risk factors behind these transactions has never been more critical for both buyers and sellers.

1.  2025 was a record year for Chinese biotech out-licensing — 157 global deals totaling $135.7B — driven by China’s significant cost and speed advantages, rising data quality, and a mature engineering ecosystem.
2. China has both the leakiest and most opaque intelligence ecosystem in global biopharma. At least four distinct layers of market intelligence surround every company and dataset, and most global dealmakers only see the first. Not all Chinese biotechs are the same. The ecosystem comprises six distinct archetypes, each with different risk profiles, decision-making styles, and negotiation dynamics, shaped heavily by whether the founder comes from a sales or R&D background.
3. Even though the dollar value may be the same, the perceived value between equity investment, upfront payments, and share swaps differ significantly. As the industry evolves beyond simple ex-China global deals, with China-based originators already accounting for ~66% of total deal value in Q1 2026, we anticipate more creative deal structures suited to the needs of both parties.

By examining these dynamics, Locust Walk aims to provide actionable insight into the evolving landscape of Chinese biotech dealmaking. Whether you are a global partner trying to decode the Chinese biotech ecosystem for the first time, or a seasoned dealmaker looking to sharpen your approach, understanding these nuances is the key to turning cross-border interest into successful transactions.

We welcome the opportunity to connect and discuss further